Categories
Change Password!
Reset Password!
The study aimed to estimate the comparative efficacy of biologics in restraining radiographic progression in patients with rheumatoid arthritis (RA).
The study results prove
that biologics had significant impact in restraining the radiographic
progression of rheumatoid arthritis as previously, some of the studies assess
the clinical and functional efficacy of biologics, but the radiological was not
fully known.
The study aimed to estimate the
comparative efficacy of biologics in restraining radiographic progression in
patients with rheumatoid arthritis (RA).
A Bayesian network meta-analysis
of published trials was conducted to examine FDA approved biologics treatment
regarding RA management using methotrexate (MTX) as the reference comparator.
A total of nine trials selected
for the base case analysis. Most
biologics (except golimumab) + MTX showed considerably lower rates of
radiographic progression at 12 months as compared to MTX alone. The adalimumab
+ MTX (-3.8) exhibited the highest mean difference in radiographic progression rates
within MTX monotherapy and biologics + MTX, whereas lowest progression rates
showed by tocilizumab + MTX (-0.7). Suppression of radiographic progression was
maintained as well.
The radiographic progression in
RA patients found to be inhibited by biologics at 12 months; although,
published evidence beyond 12 months is lacking.
J Comp Eff Res
Systematic review and network meta-analysis: effect of biologics on radiographic progression in rheumatoid arthritis.
Erin Murray et al.
Comments (0)